|
|||||
|
|
Reductions in reported deaths following the introduction of extended‐release oxycodone (OxyContin) with an abuse‐deterrent formulation |
|
| Authors: | Nelson E Sessler Jerod M Downing Hrishikesh Kale Howard D Chilcoat Todd F Baumgartner Paul M Coplan |
| Institution: | 1. Department of Risk Management and Epidemiology, Purdue Pharma L.P., , Stamford, CT, USA;2. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (Adjunct), , Baltimore, MD, USA;3. Department of Regulatory Affairs, Purdue Pharma L.P., , Stamford, CT, USA;4. Department of Clinical Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine (Adjunct), , Philadelphia, PA, USA |
| Abstract: | |
| Keywords: | OxyContin extended‐release oxycodone abuse‐deterrent overdose death pharmacovigilance pharmacoepidemiology |